Aldosterone predicts major adverse cardiovascular events in patients with acute myocardial infarction

Area of Science:

• Cardiology
• Endocrinology
• Clinical Research

Background:

• Aldosterone is linked to increased mortality in chronic heart failure.
• Previous studies in smaller cohorts suggest aldosterone correlates with adverse outcomes post-acute myocardial infarction (AMI).
• The prognostic value of aldosterone in a large AMI patient population requires further investigation.

Purpose of the Study:

• To evaluate the prognostic significance of plasma aldosterone levels.
• To assess the association between aldosterone and major adverse cardiovascular events (MACE) in post-AMI patients.
• To analyze aldosterone's role in predicting mortality and heart failure hospitalizations.

Main Methods:

• Prospective cohort study involving 955 consecutive patients admitted with AMI.
• Plasma aldosterone levels were measured upon admission.
• Major adverse cardiovascular events (MACE), including all-cause mortality, myocardial reinfarction, and heart failure hospitalization, were tracked over a 2-year follow-up period.

Main Results:

• MACE occurred in 27.3% of patients; all-cause mortality in 11.9%; and a combination of mortality and heart failure hospitalization in 18.4%.
• Patients experiencing MACE had significantly higher median aldosterone levels compared to those without (1150.1 vs 950.4 pmol/l, p=0.0118).
• Multivariate analysis revealed that higher aldosterone levels were independently associated with increased risk of MACE (HR 1.26, p=0.041), all-cause mortality (HR 1.60, p=0.008), and the combined endpoint (HR 1.50, p=0.003).

Conclusions:

• Plasma aldosterone levels are a significant prognostic marker in patients following AMI.
• Elevated aldosterone is associated with an increased risk of MACE, all-cause mortality, and heart failure hospitalizations.
• The observed increase in aldosterone secretion post-infarction may be greater than previously recognized.